Patent Incentive For Bioterrorism Research Offered In Lieberman Bill

Pharmaceuticals approved for use as anti-bioterrorism agents would be eligible for full patent term restoration under legislation introduced by Sen. Joe Lieberman (D-Conn.) on Dec. 4